News & Events

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 20, 2026, Anavex Life Sciences Corp. (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Form 10-Q”), the Company is not in c…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Departure of Chief Operating Officer On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Ch…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Termination of Chief Executive Officer On April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) terminated the employment of Christopher Missling, PhD as the Company’s Chief Executive Officer for Cause (as defined in the Em…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 20, 2026, the Board of Directors (the “ Board ”) of Anavex Life Sciences Corp., a Nevada corporation (the “ Company ”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Axel Paeger, MD, MBA, MBI as a member of the Board, effective February 23, 2026, to fill a vacancy on the Board. Dr. Paeger will b…

of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be c…

of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be c…

Entry into a Material Definitive Agreement. On July 25, 2025, Anavex Life Sciences Corp. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Sales Agent”). Pursuant to the Sales Agreement, the Company may offer and sell up to an aggregate offering price of $150,000,000 (the “Offering”) in shares of common stock, par value $0.001 per share (the “Shares”), from time to time through the Sales Agent. The issuance and sale of the Shares in the…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 3, 2025 and effective July 5, 2025, Anavex Life Sciences Corp., a Nevada corporation (the “ Company ”), entered into the Fourth Amendment to Employment Agreement (the “ Missling Amendment ”) with Christopher Missling, PhD, in his continuing capacity as Chief Executive Officer of the Company. The Missling Amendment amends the Employment Agre…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2025, Anavex Life Sciences Corp. (the “ Company ”) held its Annual Meeting of Stockholders (the “ Annual Meeting ”). At the Annual Meeting, stockholders approved an amendment (the “ Amendment ”) to the Company’s 2022 Omnibus Incentive Plan (the “ Plan ”) to (i) increase the number of shares authorized for issuance thereunder by 4,000,00…